CHI 91040

Drug Profile

CHI 91040

Alternative Names: MAPK14 inhibitor

Latest Information Update: 10 Jan 2017

Price : $50

At a glance

  • Originator Pulmagen Therapeutics
  • Class Anti-inflammatories
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Asthma

Most Recent Events

  • 03 Sep 2016 Clinical trials in Asthma in Italy (Inhalation)
  • 03 Sep 2016 Pharmacodynamics and pharmacokinetics data from a in-vitro studies presented at the 26th Annual Congress of the European Respiratory Society (ERS-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top